idw – Informationsdienst Wissenschaft
Nachrichten, Termine, Experten
Nachrichten, Termine, Experten
Scientists at the Mainz University Medical Center have discovered the potential of a typhoid vaccine for treatment of the autoimmune disease multiple sclerosis (MS)
With funding provided by the German Research Foundation (DFG) for the Collaborative Research Center/Transregio 128, researchers at the Medical Center of Johannes Gutenberg University Mainz (JGU) identified an innovative and promising therapeutic option to treat multiple sclerosis. They discovered that the protein prohibitin occurs in high concentrations on the surface of certain T cells in MS patients and that its presence is associated with stimulation of the member of the mitogen-activated protein kinase (MAPK) pathway called CRAF. The researchers were able to show in a model that the interaction between prohibitin and CRAF could be interrupted by a polysaccharide vaccine, blocking the Th17 production in pathogenic Th17 cells and promoting the proliferation of anti-inflammatory regulatory T cells. In this experimental model of MS, this led to alleviation of the severity of the condition. The team has published their findings in The EMBO Journal.
There is currently no effective remedy for multiple sclerosis (MS). The sole therapeutic option is to alleviate its symptoms. As a result, this promising new approach to treating MS, developed by a team of scientists from the Cell Biology Unit of the Mainz University Medical Center, the Department of Neurology, and the Research Center for Immunotherapy (FZI) of Johannes Gutenberg University Mainz (JGU), is attracting considerable attention.
In an experimental model of MS, the team led by Professor Frauke Zipp and Professor Krishnaraj Rajalingam of the Mainz University Medical Center found that there was significant upregulation of the proteins prohibitin 1 and 2 on the surfaces of interleukin-17 (IL-17) producing Th17 cells, a subpopulation of T cells. IL-17 is a protein secreted by a unique population of immune cells. "The increased surface expression of prohibitin 1 and 2 was associated with a similarly elevated activity of the MAP kinase CRAF and downstream MAP-kinase signal transduction. We were not only able to observe this in healthy individuals but also in Th17 cells of patients suffering from MS," Professor Frauke Zipp, Director of the Department of Neurology at the Mainz University Medical Center, pointed out. MAP kinases are activated by growth factors. They initiate a multi-stage signaling cascade, which, as a signaling pathway, regulates fundamental biological processes such as cell growth. In many cancer-related disorders, components of this signaling pathway are modified, which, among other things, can promote greater proliferation of tumor cells.
Based on these findings, the Mainz-based team hoped to discover whether and, if so, how the interaction between prohibitin and CRAF might not only be interrupted but also prevented. One approach they employed in their study was to test Vi polysaccharide, a vaccine approved by the World Health Organization (WHO) for the treatment of typhoid. This vaccine blocks the interaction between CRAF and prohibitin and thus represents a new type of kinase inhibitor. It was found that this vaccine significantly inhibits CRAF activity in treated cells. "Further investigations using this disease model allowed us to show that the number of anti-inflammatory regulatory T cells increased and, as a result, the severity of MS was significantly alleviated," explained cell biologist Professor Krishnaraj Rajalingam, head of the Cell Biology Unit at the Mainz University Medical Center. "Developing novel kinase inhibitors that target protein-protein interactions are of special interest especially in treating immune disorders. Our next goal is to apply these findings to other autoimmune diseases such as rheumatoid arthritis," added Rajalingam, who is also a Heisenberg Professor of Cell Biology and a Fellow of the JGU Gutenberg Research College.
The speaker and coordinator of the Research Center for Immunotherapy (FZI), Professor Tobias Bopp, also considers the new approach to be promising, especially as active substances that can inhibit kinases are already being used to treat patients. "Targeted treatment of tumor and autoimmune diseases with kinase inhibitors is a promising approach that is already being employed in a clinical setting."
Press contact
Oliver Kreft
Corporate Communications
Mainz University Medical Center
Langenbeckstr. 1
55131 Mainz, GERMANY
phone +49 6131 17-7424
fax +49 6131 17-3496
e-mail: pr@unimedizin-mainz.de
About the University Medical Center of Johannes Gutenberg University Mainz
The University Medical Center of Johannes Gutenberg University Mainz is the only medical facility providing supramaximal care in Rhineland-Palatinate while also functioning as an internationally recognized hub of medical science. It has more than 60 clinics, institutes, and departments that collaborate across the various disciplines. Highly specialized patient care, research, and teaching form an integral whole at the Mainz University Medical Center. Approximately 3,300 students are trained in medicine and dentistry in Mainz. With its approximately 7,500 personnel, the Mainz University Medical Center is also one of the largest employers in the region and an important driver of growth and innovation. Further information is available online at http://www.unimedizin-mainz.de/index.php?id=240&L=1
Professor Dr. Frauke Zipp
Department of Neurology
Mainz University Medical Center
Langenbeckstr. 1
55131 Mainz, GERMANY
phone +49 6131 17-7156
e-mail: frauke.zipp@unimedizin-mainz.de
Professor Dr. Krishnaraj Rajalingam
Cell Biology Unit
Mainz University Medical Center
Langenbeckstr. 1
55131 Mainz, GERMANY
phone +49 6131 17-8051
e-mail: krishna@uni-mainz.de
U. Buehler et al., Targeting prohibitins at the cell surface prevents Th17-mediated autoimmunity, The EMBO Journal 37, e99429, 26 July 2018,
DOI:10.15252/embj.201899429
Criteria of this press release:
Journalists, Scientists and scholars
Medicine
transregional, national
Research results
English
You can combine search terms with and, or and/or not, e.g. Philo not logy.
You can use brackets to separate combinations from each other, e.g. (Philo not logy) or (Psycho and logy).
Coherent groups of words will be located as complete phrases if you put them into quotation marks, e.g. “Federal Republic of Germany”.
You can also use the advanced search without entering search terms. It will then follow the criteria you have selected (e.g. country or subject area).
If you have not selected any criteria in a given category, the entire category will be searched (e.g. all subject areas or all countries).
